EGFR and neoplasm: Subsequently, it was demonstrated that the tumours with EGFR mutations are highly sensitive to gefitinib (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004) and the patients with EGFR mutations survived for a longer period after gefitinib treatment (Han et al, 2005; Mitsudomi et al, 2005).